Fibroblast growth factor‐2, derived from cancer‐associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling. Issue 9 (18th June 2020)

• Record Type: Journal Article
• Authors: Suh, Jinyoung; Kim, Do‐Hee; Lee, Yeon‐Hwa; Jang, Jeong‐Hoon; Surh, Young‐Joon
• Is Part Of: Molecular carcinogenesis. Volume 59:Issue 9(2020)
• Page Start: 1028
• Page End: 1040
• Publication Date: 2020-06-18
• Subjects: breast cancer -- cancer‐associated fibroblasts -- fibroblast growth factor 2 -- fibroblast growth factor receptor 1 -- tumor microenvironment; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.23233
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract: Cancer‐associated fibroblasts (CAFs) constitute a major compartment of the tumor microenvironment. In the present study, we investigated the role for CAFs in breast cancer progression and underlying molecular mechanisms. Human breast cancer MDA‐MB‐231 cells treated with the CAF‐conditioned media manifested a more proliferative phenotype, as evidenced by enhanced messenger RNA (mRNA) expression of Cyclin D1, c‐Myc, and proliferating cell nuclear antigen. Analysis of data from The Cancer Genome Atlas revealed that fibroblast growth factor‐2 (FGF2) expression was well correlated with the presence of CAFs. We noticed that the mRNA level of FGF2 in CAFs was higher than that in normal fibroblasts. FGF2 exerts its biological effects through interaction with FGF receptor 1 (FGFR1). In the breast cancer tissue array, 42% estrogen receptor‐negative patients coexpressed FGF2 and FGFR1, whereas only 19% estrogen receptor‐positive patients exhibited coexpression. CAF‐stimulated MDA‐MB‐231 cell migration and invasiveness were abolished when FGF2‐neutralizing antibody was added to the conditioned media of CAFs. In a xenograft mouse model, coinjection of MDA‐MB‐231 cells with activated fibroblasts expressing FGF2 dramatically enhanced tumor growth, and this was abrogated by silencing of FGFR1 in cancer cells. In addition, treatment of MDA‐MB‐231 cells with FGF2 enhanced expression of Cyclin D1, a key molecule involved in cell cycle progression. FGF2‐induced cell migration and upregulation of Cyclin D1 were abolished by siRNA‐mediated FGFR1 silencing. Taken together, the above findings suggest that CAFs promote growth, migration and invasion of MDA‐MB‐231 cells via the paracrine FGF2‐FGFR1 loop in the breast tumor microenvironment.